On May 15, 2025, freshman Republican Congressman Rob Bresnahan of Pennsylvania sold up to $130,000 worth of stock in four of the country's largest Medicaid managed care companies: Centene, Elevance Health, UnitedHealth, and CVS Health. Those four companies oversee roughly half of all Medicaid managed care in the United States. One week later, on May 22, Bresnahan voted for Trump's budget bill, which cut nearly $1 trillion from Medicaid. He voted with all but two House Republicans.
Bresnahan also sold between $100,000 and $250,000 worth of bonds issued by the Allegheny County Hospital Development Authority, tied to the University of Pittsburgh Medical Center. UPMC is one of the largest hospital systems in Pennsylvania. Medicaid reimbursements make up a significant portion of its revenue. The same legislation Bresnahan voted for reduced those reimbursements.
His explanation: his financial advisors made the decisions. He says he never instructed them what to buy or sell. That may be legally accurate. It does not explain the timing.
A Pattern the Data Makes Hard to Ignore
Bresnahan's trades have drawn sustained scrutiny across multiple transactions and multiple votes. A September 2025 analysis documented earlier instances where his financial disclosures showed sales that preceded negative legislative votes on affected industries. Constituents raised the issue at a December 2025 town hall. His answers did not satisfy them. By April 2026, reports indicate he stands to pocket millions from the tax cut provisions in the same budget bill he voted for.
The pattern, repeated across multiple transactions, suggests either extraordinary coincidence or a financial management strategy so closely calibrated to congressional activity that the distinction between "informed trading" and "insider trading" becomes difficult to maintain. The STOCK Act does not require proof of intent. It requires timely disclosure and prohibits trades on material non-public information. The question of whether a congressman's financial advisor can use that congressman's public committee activity to time trades on his behalf is one Congress has declined to answer.
The Medicaid Cut Itself
The budget bill Bresnahan voted for cut nearly $1 trillion from Medicaid over ten years. Pennsylvania has approximately 3.7 million Medicaid enrollees. The cuts are expected to reduce access to coverage for low-income adults, children, and people with disabilities across the state. UPMC, whose bonds Bresnahan sold before the vote, faces reduced reimbursement revenue as a direct result of the legislation his vote helped pass.
Bresnahan is a freshman congressman running for reelection in 2026 in a competitive district. The people whose coverage is at risk from the legislation he supported are his constituents.
No Prosecution, No Reform, No Accountability
No member of Congress has ever been prosecuted for insider trading under the STOCK Act. The penalties for disclosure violations are minimal. The Stop Insider Trading Act, which would have addressed these gaps, missed its Q1 2026 deadline and is currently stalled in both chambers.
Until stronger law passes, or until a federal prosecutor decides the STOCK Act means what it says, members of Congress can continue selling the stocks of the industries they regulate, days before their votes, and call it coincidence.
Sources:
NBC News: Rep. Rob Bresnahan sold stock in several Medicaid providers before voting for cuts
Keystone News Room: New ad calls out Bresnahan's decision to sell Medicaid stocks before gutting the program
Keystone News Room: Bresnahan pockets millions after voting to cut his own taxes
New Republic: Republican Votes for Budget After Dumping Medicaid-Related Stock
Keep reading
This is independent, sourced accountability reporting by Impeach 47. No corporate owners, no paywall.
Get new posts delivered free by email: impeachh47.substack.com.
Follow on X: @Impeach_47.
If this reporting is useful, the way you support us is simple: wear the movement. Every hat, shirt, and sticker from impeachtrump.earth is a walking billboard and the thing that keeps this research fed.
0 comments